The week in pharma: action, reaction and insight – week to May 13, 2022
By Barbara Obstoj-Cardwell. Editor
In the news last week, on Monday Johnson & Johnson subsidiary Janssen announced that it was terminating a license agreement with Denmark’s Bavarian Nordic on potential vaccines for hepatitis B and HPV. On the M&A front, having already invested in the biotech firm, US pharma giant Pfizer last Tuesday announced a full acquisition of Biohaven Pharmaeutical in a deal valuing the company at $11.6 billion, and giving it rights to the migraine drug Nurtec ODT. Also, Japanese drugmaker Otsuka’s Taiho unit has reached an agreement to acquire part of Cullinan Oncology and, in doing so, will regain rights to a lung cancer candidate previously offloaded to the US firm. Meantime, Swiss pharma giant Roche released disappointing Phase III results for its TIGIT blocker tiragolumab in lung cancer.
J&J ducks out of Bavarian Nordic vaccine partnerships
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze